A novel technology using nano-sized ultrafine water clusters is associated with significant reduction in the erythema that ...
In a small, nonrandomized controlled trial, the injectable calcitonin gene-related peptide (CGRP) inhibitor erenumab significantly reduced treatment-resistant flushing and erythema associated with ...
Please provide your email address to receive an email when new articles are posted on . Flushing and erythema were reduced in patients using erenumab, a CGRP receptor antagonist. Adverse events were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results